Testing afatinib for head and neck cancer in Fanconi anemia patients
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether the targeted drug afatinib can shrink advanced head and neck cancers in people who also have Fanconi anemia. It is for patients whose tumors cannot be surgically removed and have not responded to or cannot have other standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Fanconi anemia.
- You have advanced squamous cell carcinoma of the head or neck that cannot be removed by surgery.
- Your tumor can be measured on a CT scan or MRI.
- You have at least one measurable tumor spot.
- You are 18 years or older.
- You have adequate kidney, liver, and blood cell counts as confirmed by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) plus targeted radiation before surgery for head and neck cancer. The goal is to see if this approach can shrink the tumor or help the surgery be more effective.
This trial tests whether giving a slightly different schedule of radiation (more frequent, smaller doses) can improve treatment for people with large head and neck cancers. It is for patients who are getting radiation as their main treatment, sometimes with chemotherapy as well.
This trial is for people with head and neck cancer that has not spread to distant parts of the body. It is a non-treatment study that will look at the molecular features of your tumor from a biopsy sample to help guide future treatment decisions.
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
This trial tests a combination of two medications, ficerafusp alfa and nivolumab, for people with head and neck cancer that has progressed after platinum-based treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Fanconi Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.